At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 13, 2026 at 16:05 ET
CEO John Oyler filed an amended Schedule 13G reporting beneficial ownership of 54,065,077 ordinary shares (3.6% of shares outstanding) as of September 30, 2026. The filing is a routine periodic update with no change in stake direction disclosed in the document, and it follows strong Q3 earnings reported eight days earlier.
- John Oyler beneficially owns 54,065,077 ordinary shares of BeOne Medicines Ltd.
- Stake represents 3.6% of 1,483,318,035 ordinary shares outstanding as of September 30, 2026.
- Ownership includes shares held directly, in trusts, retirement accounts, and options/RSUs exercisable within 60 days.
- Filing is an amendment to Schedule 13G, indicating no change in passive investor status.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access